Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,809,273

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.68 -0.01 (-0.01%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Apple, NIKE, Walt Disney, PG and MRK

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, NIKE, Walt Disney, PG and MRK

Sweta Killa headshot

5 Sectors Set to Boom on Coronavirus Vaccine Optimism: Top Picks

by Sweta Killa

While the prospect of a COVID-19 treatment will lead to broad-based gains, some investing areas are expected to benefit the most.

Merck's Keytruda Gets Approval for Esophageal Cancer in Japan

by Zacks Equity Research

Merck's (MRK) Keytruda receives approval in Japan as second-line treatment for esophageal squamous cell carcinoma. A new dosing regimen also receives approval in the country.

Sweta Killa headshot

Dow Reclaims 28,000: 5 Stocks Driving the ETF Rally

by Sweta Killa

The Dow Jones Industrial Index ended above 28,000 for the first time in six months.

Kinjel Shah headshot

Pharma Stock Roundup: SNY, JNJ Acquisition Deals, FDA Approvals

by Kinjel Shah

J&J (JNJ) proposes to buy Momenta Pharmaceuticals while Sanofi (SNY) offers to buy Principia Biopharma

Merck's Keytruda Positive in First-Line Esophageal Cancer Study

by Zacks Equity Research

Merck's (MRK) Keytruda improves overall survival and progression-free survival compared to current standard of care in first-line metastatic esophageal cancer patients.

Alkermes Starts Phase II Study on ALKS 4230 for Solid Tumors

by Zacks Equity Research

Alkermes (ALKS) initiates phase II ARTISTRY-3 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy in patients with advanced solid tumors.

AstraZeneca's Imfinzi Gets Priority Tag for 4-Week Dosing

by Zacks Equity Research

The FDA grants priority review to AstraZeneca's (AZN) sBLA seeking approval of Imfinzi for a four-week fixed-dose regimen for its approved indications in bladder cancer and non-small cell lung cancer.

Bristol Myers & Dragonfly Team Up for Immunotherapy Program

by Zacks Equity Research

Bristol Myers (BMY) collaborates with Dragonfly Therapeutics, Inc. for its experimental immunotherapy program.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approval for Roche's SMA Drug & Other Updates

by Kinjel Shah

Teaser: FDA approves Roche's (RHHBY) new SMA drug, Evrysdi (risdiplam).

Kinjel Shah headshot

Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes

by Kinjel Shah

The Zacks Large-Cap Pharmaceuticals industry ranks in the bottom 26% of more than 250 Zacks industries.

Esperion (ESPR) Q2 Earnings Top, Drug Sales Hurt by Coronavirus

by Zacks Equity Research

Esperion Therapeutics (ESPR) reports mixed second-quarter results as it beats estimates for earnings and misses for sales.

Iovance (IOVA) Q2 Earnings Beat Estimates, Pipeline in Focus

by Zacks Equity Research

Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.

Sweta Killa headshot

Pharma ETFs Soar on Robust Q2 Earnings

by Sweta Killa

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Nektar's (NKTR) Q2 Earnings Beat, Bempeg Makes Progress

by Zacks Equity Research

Nektar (NKTR) reports encouraging second-quarter 2020 results. The company continues to progress with its pipeline candidates.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV, MRK Q2 Earnings & Coronavirus Updates in Focus

by Kinjel Shah

Sanofi (SNY)/Glaxo (GSK) and J&J (JNJ) sign deals with U.S. government for coronavirus vaccine candidate. Several drugmakers announce second-quarter results.

Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Exelixis (EXEL) beats on earnings and sales in the second quarter.

Novo Nordisk's (NVO) Q2 Earnings Beat Estimates, Sales Miss

by Zacks Equity Research

Novo Nordisk's (NVO) earnings surpass estimates but revenues miss the same in the second quarter of 2020.

Moderna (MRNA) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Moderna (MRNA) reports narrower-than-expected second-quarter loss. Shares decline presumably on absence of any new data on coronavirus vaccine candidate.

Bristol-Myers (BMY) Q2 Earnings Beat, 2020 Earnings View Up

by Zacks Equity Research

Bristol-Myers (BMY) beats on earnings and sales in the second quarter on the strength of Revlimid and Eliquis.

Corcept (CORT) Q2 Earnings Top Estimates, Revenues Miss Mark

by Zacks Equity Research

Corcept's (CORT) earnings trump estimates for the second quarter of 2020 while revenues fall shy of the same.

Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.

Benjamin Rains headshot

3 Diverse Large-Cap Stocks to Buy Now to Boost Your Long-Term Portfolio

by Benjamin Rains

Investors should consider adding a few large-cap names that are prepared to grow for years to come. These three stocks also pay dividends and provide exposure to three very different and vital industries...

Sweta Killa headshot

5 Growth ETFs & Stocks to Ride the Market Rally

by Sweta Killa

Growth investing has taken the lead over value and is likely to stay given a slew of reasons.

Will Eliquis, Revlimid Drive Bristol-Myers (BMY) Q2 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2020 results.